Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 226
Ph III recruiting: 25
Growth YoY: +3.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 51–56 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01786226	Mifepristone to Treat Uterine Fibroids	terminated	Phase 2 / Phase 3	220	Mediterranea Medica S. L.OTHER	1	Sep 5, 2014	clinicaltrials
NCT00958893	An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext	terminated	Phase 2	4	Repros Therapeutics Inc.INDUSTRY	1	Aug 25, 2014	clinicaltrials